7th Jan 2021 13:51
Avacta Group PLC - Wetherby, England-based pre-clinical stage biotechnology company - Enters license agreement with Point Biopharma Inc to provide access to its pre|Cision technology for the development of tumour-activated radiopharmaceuticals. Says pre|Cision technology has the potential to improve the tolerability and achieve better clinical outcomes for patients by targeting radioligand treatment, which is a form of radiation therapy, more specifically to cancer cells.
"The clinical and commercial rationale for our pre|Cision prodrug platform is to improve the safety and efficacy of many existing drugs, as well as generating a pipeline of new and novel cancer therapies. In oncology, we believe that this approach will result in better response rates for monotherapies, and a greater safety margin, to enable their use with a larger patient population and as part of combination therapies," says Chief Executive Alastair Smith.
Current stock price: 130.55 pence
Year-to-date change: up 15%
By Zoe Wickens; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Avacta Group